Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study.
Ling YangYuan FangYuan LuoMeng FuKai ShenZhu LuoPublished in: Expert opinion on investigational drugs (2024)
The study was registered on the ClinicalTrials.gov (identifier: NCT04480762).